What is ALS Phase 2 Study KNS-760704 CL211?

Category: Others

false

See also: ALS Phase 2 Study KNS-760704 CL201

NCT00931944 is an open label, safety and tolerability, study evaluating the drug KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The drug KNS-760704 is now known as dexpramipexole. Other study ID include: KNS-760704-CL211.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
1
Moderate
0
Mild
0
None
0

Commonly reported side effects and conditions associated with ALS Phase 2 Study KNS-760704 CL211

Side effect Patients
Loss of appetite 1
Ringing in ears (tinnitus) 1

Why patients stopped taking ALS Phase 2 Study KNS-760704 CL211

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
Side effects too severe 1
See 1 patient who's stopped using ALS Phase 2 Study KNS-760704 CL211

Duration

Stopped using ALS Phase 2 Study KNS-760704 CL211

Duration Patients
6 months - 1 year 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 0
Not at all hard to take 0
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 0
Last updated:
There are no evaluations for ALS Phase 2 Study KNS-760704 CL211.